131 related articles for article (PubMed ID: 30704928)
1. A PARP inhibitor in pancreatic cancer: Enhancement anti-tumour activity of chemoradiation therapy against pancreatic cancer?
Furuse J
EBioMedicine; 2019 Feb; 40():9-10. PubMed ID: 30704928
[No Abstract] [Full Text] [Related]
2. What is the role of PARP inhibitors in pancreatic cancer?
Halder R; Shroff RT
Expert Rev Anticancer Ther; 2020 Nov; 20(11):913-918. PubMed ID: 32865047
[No Abstract] [Full Text] [Related]
3. Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts.
Lohse I; Kumareswaran R; Cao P; Pitcher B; Gallinger S; Bristow RG; Hedley DW
PLoS One; 2016; 11(12):e0167272. PubMed ID: 28033382
[TBL] [Abstract][Full Text] [Related]
4. PARP Inhibitors in Pancreatic Cancer.
Brown TJ; Reiss KA
Cancer J; 2021 Nov-Dec 01; 27(6):465-475. PubMed ID: 34904809
[TBL] [Abstract][Full Text] [Related]
5. Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers.
Hastak K; Bhutra S; Parry R; Ford JM
Oncotarget; 2017 Apr; 8(16):26344-26355. PubMed ID: 28412751
[TBL] [Abstract][Full Text] [Related]
6. PARP Inhibitor Drugs in the Treatment of Breast, Ovarian, Prostate and Pancreatic Cancers: An Update of Clinical Trials.
Kamel D; Gray C; Walia JS; Kumar V
Curr Drug Targets; 2018; 19(1):21-37. PubMed ID: 28699513
[TBL] [Abstract][Full Text] [Related]
7. Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer.
Sulai NH; Tan AR
Clin Adv Hematol Oncol; 2018 Jul; 16(7):491-501. PubMed ID: 30067621
[TBL] [Abstract][Full Text] [Related]
8. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
[TBL] [Abstract][Full Text] [Related]
9. [
Tan KV
Radiol Imaging Cancer; 2022 Sep; 4(5):e229018. PubMed ID: 36112035
[No Abstract] [Full Text] [Related]
10. Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities.
Rajawat J; Shukla N; Mishra DP
Med Res Rev; 2017 Nov; 37(6):1461-1491. PubMed ID: 28510338
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice.
van de Ven M; van der Burg E; van der Gulden H; Klarenbeek S; Bouwman P; Jonkers J
J Pathol; 2017 Mar; 241(4):511-521. PubMed ID: 27943283
[TBL] [Abstract][Full Text] [Related]
12. Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials.
de Haan R; Pluim D; van Triest B; van den Heuvel M; Peulen H; van Berlo D; George J; Verheij M; Schellens JHM; Vens C
Radiother Oncol; 2018 Mar; 126(3):443-449. PubMed ID: 29150161
[TBL] [Abstract][Full Text] [Related]
13. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
14. Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.
Gunderson CC; Moore KN
Future Oncol; 2015; 11(5):747-57. PubMed ID: 25757679
[TBL] [Abstract][Full Text] [Related]
15. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.
Miller RE; Ledermann JA
Clin Adv Hematol Oncol; 2016 Aug; 14(8):619-27. PubMed ID: 27487106
[TBL] [Abstract][Full Text] [Related]
16. Outcomes and tolerability of chemoradiation therapy for pancreatic cancer patients aged 75 years or older.
Miyamoto DT; Mamon HJ; Ryan DP; Willett CG; Ancukiewicz M; Kobayashi WK; Blaszkowsky L; Fernandez-del Castillo C; Hong TS
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1171-7. PubMed ID: 19800182
[TBL] [Abstract][Full Text] [Related]
17. Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer.
Yang SH; Kuo TC; Wu H; Guo JC; Hsu C; Hsu CH; Tien YW; Yeh KH; Cheng AL; Kuo SH
World J Gastroenterol; 2016 Aug; 22(32):7275-88. PubMed ID: 27621574
[TBL] [Abstract][Full Text] [Related]
18. Posttranscriptional Regulation of
Chand SN; Zarei M; Schiewer MJ; Kamath AR; Romeo C; Lal S; Cozzitorto JA; Nevler A; Scolaro L; Londin E; Jiang W; Meisner-Kober N; Pishvaian MJ; Knudsen KE; Yeo CJ; Pascal JM; Winter JM; Brody JR
Cancer Res; 2017 Sep; 77(18):5011-5025. PubMed ID: 28687616
[TBL] [Abstract][Full Text] [Related]
19. PARP inhibitors in ovarian and other cancers.
Plummer R
Clin Adv Hematol Oncol; 2015 May; 13(5):285-7. PubMed ID: 26352770
[No Abstract] [Full Text] [Related]
20. Enhancement of Soft Tissue Sarcoma Cell Radiosensitivity by Poly(ADP-ribose) Polymerase-1 Inhibitors.
Mangoni M; Sottili M; Salvatore G; Meattini I; Desideri I; Greto D; Loi M; Becherini C; Garlatti P; Delli Paoli C; Dominici L; Gerini C; Scoccianti S; Bonomo P; Silvano A; Beltrami G; Campanacci D; Livi L
Radiat Res; 2018 Nov; 190(5):464-472. PubMed ID: 30067444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]